Q2 2025 · 13F-HR
Nan Fung Group Holdings Ltdholdings as filed
Filed 2025-08-13 · accession 0001012975-25-000440
$63.4M
Reported value
20
Positions
2025-06-30
Period end
The Brief · Nan Fung Group Holdings Ltd · Q2 2025
AI · grounded in 13F
Nan Fung Group Holdings Ltd established a new position in HRMY worth $11.6M. The fund also initiated new stakes in ILMN for $11.4M and OCS for $9.9M. Other new additions include INCY, ONC, and MDGL.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $11.6M | 18.4% | 368,665 | Common | SOLE |
| 452327109 | ILMN | ILLUMINA INC | $11.4M | 17.9% | 119,196 | Common | SOLE |
| H5870P102 | OCS | OCULIS HOLDING AG | $10.0M | 15.7% | 514,702 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $4.0M | 6.34% | 59,022 | Common | SOLE |
| 07725L102 | ONC | BEONE MEDICINES LTD | $3.8M | 6.00% | 15,722 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $3.6M | 5.66% | 11,872 | Common | SOLE |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS IN | $3.4M | 5.30% | 664,610 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $3.1M | 4.89% | 49,120 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $2.3M | 3.70% | 13,600 | Common | SOLE |
| 34385P108 | LAB | STANDARD BIOTOOLS INC | $2.3M | 3.56% | 1,883,179 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $2.2M | 3.50% | 102,984 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $1.5M | 2.43% | 2,800 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $1.3M | 2.12% | 30,875 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $708,318 | 1.12% | 19,253 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $591,950 | 0.93% | 63,719 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $479,154 | 0.76% | 68,943 | Common | SOLE |
| 097702203 | BOLT | BOLT BIOTHERAPEUTICS INC | $336,662 | 0.53% | 58,347 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $329,831 | 0.52% | 49,082 | Common | SOLE |
| 753018100 | RANI | RANI THERAPEUTICS HLDGS INC | $253,653 | 0.40% | 493,584 | Common | SOLE |
| 09769B206 | BSLK | BOLT PROJS HLDGS INC | $114,484 | 0.18% | 40,597 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.